Inhibition of inflammation by IL-6 blockade in xenotransplantation

被引：0

作者：

Iwanczyk, Zuzanna ^{[1
]}

Hara, Hidetaka ^{[2
]}

Cooper, David K. C. ^{[1
]}

Maenaka, Akihiro ^{[1
]}

机构：

[1] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Transplantat Sci, Dept Surg, Boston, MA USA

[2] Yunnan Agr Univ, Coll Vet Med, Kunming, Yunnan, Peoples R China

来源：

CYTOKINE | 2025年 / 189卷

关键词：

IL-6; Inflammation; Pig; Rejection; Xenotransplantation; ANTI-INTERLEUKIN-6 RECEPTOR ANTIBODY; SYSTEMIC INFLAMMATION; RHEUMATOID-ARTHRITIS; MEDIATED REJECTION; T-CELLS; INTERLEUKIN-6; TOCILIZUMAB; CYTOKINE; ACTIVATION; MECHANISMS;

D O I：

10.1016/j.cyto.2025.156897

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The inflammatory cytokine interleukin 6 (IL-6) plays a role in both acute and chronic organ allotransplant rejection. Data suggest that IL-6 inhibition may help prevent or reverse rejection, with large multi-center trials now underway. However, the evidence for the benefit of IL-6 inhibitors in xenotransplantation is limited. IL-6 inhibition has been explored in nonhuman-primate models of xenotransplantation, but no clear consensus exists on its efficacy or the best mode of IL-6 inhibition (anti-IL-6 antibodies, or through IL-6 receptor [IL-6R] blockade). Extra considerations for IL-6 blockade exist in xenotransplantation, as both recipient (human) and xenograftderived (porcine) IL-6 may play roles. The systemic inflammation seen in xenograft recipients (SIXR) contributes to significant morbidity and mortality for the recipient through coagulation dysfunction and augmentation of the immune response. Anti-IL-6 antibodies (e.g., siltuximab) bind to human IL-6 and prevent IL-6R activation, but do not bind to porcine IL-6, and so have no effect in preventing graft-driven inflammatory processes. In contrast, IL6R inhibitors (e.g., tocilizumab) inhibit IL-6 activity by blocking binding of human and porcine IL-6 to human IL6R. Although IL-6R blockade cannot prevent the effect of IL-6 on porcine cells, it probably prevents graft-derived IL-6 from contributing to an inflammatory response in the host. This review outlines the role of IL-6 in xenotransplantation and discusses mechanisms for inhibiting IL-6 to improve recipient survival.

引用

页数：9

共 78 条

[31]

Rodriguez-Ramirez S., Al Jurdi A., Konvalinka A., Riella L.V., Antibody-mediated rejection: prevention, monitoring and treatment dilemmas, Curr. Opin. Organ Transplant., 27, pp. 405-414, (2022)

[32]

Cooper D.K.C., Hara H., Iwase H., Yamamoto T., Wang Z., Jagdale A., Bikhet M.H., Nguyen H.Q., Foote J.B., Paris W.D., Ayares D., Kumar V., Anderson D.J., Locke J.E., Eckhoff D.E., Pig kidney xenotransplantation: progress toward clinical trials, Clin. Transpl., 35, (2021)

[33]

Dienz O., Eaton S.M., Bond J.P., Neveu W., Moquin D., Noubade R., Briso E.M., Charland C., Leonard W.J., Ciliberto G., Teuscher C., Haynes L., Rincon M., The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4+ T cells, J. Exp. Med., 206, pp. 69-78, (2009)

[34]

Jordan S.C., Ammerman N., Choi J., Huang E., Peng A., Sethi S., Najjar R., Kim I., Toyoda M., Kumar S., Lim K., Vo A., The role of novel therapeutic approaches for prevention of allosensitization and antibody-mediated rejection, Am. J. Transplant., 20, pp. 42-56, (2020)

[35]

Wu G., Chai N., Kim I., Klein A.S., Jordan S.C., Monoclonal anti-interleukin-6 receptor antibody attenuates donor-specific antibody responses in a mouse model of allosensitization, Transplant. Immunol., 28, pp. 138-143, (2013)

[36]

Lavacca A., Presta R., Gai C., Mella A., Gallo E., Camussi G., Abbasciano I., Barreca A., Caorsi C., Fop F., Messina M., Rossetti M., Biancone L., Early effects of first-line treatment with anti-interleukin-6 receptor antibody tocilizumab for chronic active antibody-mediated rejection in kidney transplantation, Clin. Transpl., 34, (2020)

[37]

Iwase H., Ekser B., Zhou H., Liu H., Satyananda V., Humar R., Humar P., Hara H., Long C., Bhama J.K., Bajona P., Wang Y., Wijkstrom M., Ayares D., Ezzelarab M.B., Cooper D.K.C., Further evidence for sustained systemic inflammation in xenograft recipients (SIXR), Xenotransplantation, 22, pp. 399-405, (2015)

[38]

Li T., Lee W., Hara H., Long C., Ezzelarab M., Ayares D., Huang H., Wang Y., Esmon C.T., Cooper D.K.C., Iwase H., An investigation of extracellular histones in pig-to-baboon organ xenotransplantation, Transplantation, 101, pp. 2330-2339, (2017)

[39]

Hunter C.A., Jones S.A., IL-6 as a keystone cytokine in health and disease, Nat. Immunol., 16, pp. 448-457, (2015)

[40]

Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Muller-Newen G., Schaper F., Principles of interleukin (IL)-6-type cytokine signalling and its regulation, Biochem. J., 374, pp. 1-20, (2003)

← 1 2 3 4 5 6 7 8 →